Fig. 2From: Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort studySurvival curves for the primary outcome (time to severity). Comparative groups between a age < 48 years vs age ≥ 48, b male vs female, c arbidol vs control, d interferon alpha-1b (IFN-α) vs control, e lopinavir–ritonavir (LPV/r) vs control, f ribavirin vs controlBack to article page